Patent ID: 7427485
Filing Date: 2008-09-23
Classification: A61P,C12Q,G01N

Abstract:
1. A method for identifying an agent to be tested as an atypical anti-psychotic treatment for a psychotic disorder, comprising: contacting striatal cells or tissue with the agent to be tested, detecting the phosphorylation levels of DARPP-32 at Thr75, ERK1 at Thr202 and Tyr204, ERK2 at Thr185 and Tyr187 and CREB at Ser133 in the striatal cells or tissue contacted with the agent; detecting the phosphorylation levels of DARPP-32 at Thr75, ERK1 at Thr202 and Tyr204, ERK2 at Thr185 and Tyr187 and CREB at Ser133 in the striatal cells or tissue not contacted with an agent; determining whether a predetermined criteria has been met, wherein the criteria comprises a phosphorylation level of Thr75 in DARPP-32 in the treated cells or tissue greater than the untreated cells or tissue, and phosphorylation levels of Thr202 and Tyr204 in ERK1, Thr185 and Tyr187 in ERK2 and Ser133 in CREB in the treated cells or tissue less than the untreated cells or tissue; and wherein the agent is identified for testing as an atypical anti-psychotic treatment if the agent meets the criteria.